These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33738072)

  • 1. Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes.
    Zhang X; Zhu B; Guo L; Bakaj I; Rankin M; Ho G; Kauffman J; Lee SP; Norquay L; Macielag MJ
    ACS Med Chem Lett; 2021 Mar; 12(3):451-458. PubMed ID: 33738072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 Antagonists.
    Zhu B; Zhang X; Guo L; Rankin M; Bakaj I; Ho G; Lee SP; Norquay L; Macielag M
    ACS Med Chem Lett; 2022 Jan; 13(1):111-117. PubMed ID: 35059130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists.
    Zhang X; Zhu B; Guo L; Bakaj I; Rankin M; Ho G; Kauffman J; Lee SP; Norquay L; Macielag M
    Bioorg Med Chem Lett; 2021 Sep; 47():128172. PubMed ID: 34091043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.
    Jin J; Morales-Ramos A; Eidam P; Mecom J; Li Y; Brooks C; Hilfiker M; Zhang D; Wang N; Shi D; Tseng PS; Wheless K; Budzik B; Evans K; Jaworski JP; Jugus J; Leon L; Wu C; Pullen M; Karamshi B; Rao P; Ward E; Laping N; Evans C; Leach C; Holt D; Su X; Morrow D; Fries H; Thorneloe K; Edwards R
    ACS Med Chem Lett; 2010 Oct; 1(7):316-20. PubMed ID: 24900213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
    Pfefferkorn JA; Lou J; Minich ML; Filipski KJ; He M; Zhou R; Ahmed S; Benbow J; Perez AG; Tu M; Litchfield J; Sharma R; Metzler K; Bourbonais F; Huang C; Beebe DA; Oates PJ
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3247-52. PubMed ID: 19435665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists.
    Morales-Ramos ÁI; Li YH; Hilfiker M; Mecom JS; Eidam P; Shi D; Tseng PS; Brooks C; Zhang D; Wang N; Jaworski JP; Morrow D; Fries H; Edwards R; Jin J
    Bioorg Med Chem Lett; 2011 May; 21(10):2806-11. PubMed ID: 21514150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists.
    Song F; Xu G; Gaul MD; Zhao B; Lu T; Zhang R; DesJarlais RL; DiLoreto K; Huebert N; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
    Bioorg Med Chem Lett; 2019 Aug; 29(15):1974-1980. PubMed ID: 31138472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.
    Li YH; Tseng PS; Evans KA; Jaworski JP; Morrow DM; Fries HE; Wu CW; Edwards RM; Jin J
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6744-7. PubMed ID: 20926294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion.
    Kimple ME; Keller MP; Rabaglia MR; Pasker RL; Neuman JC; Truchan NA; Brar HK; Attie AD
    Diabetes; 2013 Jun; 62(6):1904-12. PubMed ID: 23349487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.
    Caporarello N; Salmeri M; Scalia M; Motta C; Parrino C; Frittitta L; Olivieri M; Cristaldi M; Avola R; Bramanti V; Toscano MA; Anfuso CD; Lupo G
    PLoS One; 2016; 11(9):e0159874. PubMed ID: 27631977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel series of indazole-/indole-based glucagon receptor antagonists.
    Lin S; Zhang F; Jiang G; Qureshi SA; Yang X; Chicchi GG; Tota L; Bansal A; Brady E; Trujillo M; Salituro G; Miller C; Tata JR; Zhang BB; Parmee ER
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4143-7. PubMed ID: 26303893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery of Pyridone and Pyridazone Heterocycles as γ-Secretase Modulators.
    Huang X; Aslanian R; Zhou W; Zhu X; Qin J; Greenlee W; Zhu Z; Zhang L; Hyde L; Chu I; Cohen-Williams M; Palani A
    ACS Med Chem Lett; 2010 Jul; 1(4):184-7. PubMed ID: 24900193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
    Wang L; Pratt JK; Soltwedel T; Sheppard GS; Fidanze SD; Liu D; Hasvold LA; Mantei RA; Holms JH; McClellan WJ; Wendt MD; Wada C; Frey R; Hansen TM; Hubbard R; Park CH; Li L; Magoc TJ; Albert DH; Lin X; Warder SE; Kovar P; Huang X; Wilcox D; Wang R; Rajaraman G; Petros AM; Hutchins CW; Panchal SC; Sun C; Elmore SW; Shen Y; Kati WM; McDaniel KF
    J Med Chem; 2017 May; 60(9):3828-3850. PubMed ID: 28368119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human islets through a SIRT1-dependent mechanism.
    Vetterli L; Brun T; Giovannoni L; Bosco D; Maechler P
    J Biol Chem; 2011 Feb; 286(8):6049-60. PubMed ID: 21163946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor.
    Gu X; Xu J; Zhu L; Bryson T; Yang XP; Peterson E; Harding P
    Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27502370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin EP3 receptor signaling is required to prevent insulin hypersecretion and metabolic dysfunction in a non-obese mouse model of insulin resistance.
    Wisinski JA; Reuter A; Peter DC; Schaid MD; Fenske RJ; Kimple ME
    Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E479-E489. PubMed ID: 34229444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK.
    Rozentul N; Avrahami Y; Shubely M; Levy L; Munder A; Cohen G; Cerasi E; Sasson S; Gruzman A
    Pharm Res; 2017 Dec; 34(12):2873-2890. PubMed ID: 28983714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.
    Sugimoto I; Kambe T; Okino T; Obitsu T; Ohta N; Nishiyama T; Kinoshita A; Fujimoto T; Egashira H; Yamane S; Shuto S; Tani K; Maruyama T
    ACS Med Chem Lett; 2017 Jan; 8(1):107-112. PubMed ID: 28105284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeic acid, naringenin and quercetin enhance glucose-stimulated insulin secretion and glucose sensitivity in INS-1E cells.
    Bhattacharya S; Oksbjerg N; Young JF; Jeppesen PB
    Diabetes Obes Metab; 2014 Jul; 16(7):602-12. PubMed ID: 24205999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol long-term treatment differentiates INS-1E beta-cell towards improved glucose response and insulin secretion.
    Casimir M; Chaffard G; Maechler P
    Pflugers Arch; 2019 Feb; 471(2):337-345. PubMed ID: 30310992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.